Insurance Switching and Mismatch Between the Costs and Benefits of New Technologies

The American Journal of Managed Care, December 2017

Managing Principal Noam Kirson coauthored a paper on insurance switching and coverage challenges for innovative therapies with Professor David Cutler of Harvard University, Michael Ciarmetaro and Robert Dubois of the National Pharmaceutical Council, and Genia Long. The study illustrates how emerging high-cost transformative therapies can exacerbate gaps between US payers when the benefits of treatment materialize over time, and highlights the need for creative approaches to ensure appropriate access to cost-effective therapies, adequate incentives for future treatment development, and sustainable payer economics.

View the paper


Cutler D, Ciarametaro M, Long G, Kirson N, Dubois R